Literature DB >> 22878874

The impact of depressive symptoms on recovery and outcome of hospitalised COPD exacerbations.

Andriana I Papaioannou1, Konstantinos Bartziokas, Stamatoula Tsikrika, Foteini Karakontaki, Emmanouil Kastanakis, Winston Banya, Aikaterini Haniotou, Spyros Papiris, Stelios Loukides, Vlassis Polychronopoulos, Konstantinos Kostikas.   

Abstract

The impact of depressive symptoms on outcomes of acute exacerbations of chronic obstructive pulmonary disease (AECOPD) has not been thoroughly evaluated in prospective studies. We prospectively enrolled 230 consecutive patients hospitalised for AECOPD, without previous diagnosis of depression. Depressive symptoms were evaluated with Beck's depression inventory. Pulmonary function tests, arterial blood gases, COPD assessment test (CAT) and Borg dyspnoea scale were recorded on admission and on days 3, 10 and 40. Patients were evaluated monthly for 1 year. Patients with depressive symptoms required longer hospitalisation (mean ± sd 11.6 ± 3.7 versus 5.6 ± 4.1 days, p<0.001). Clinical variables improved during the course of AECOPD, but depressive symptoms on admission had a significant impact on dyspnoea (p<0.001) and CAT score (p = 0.012) improvement. Patients with depressive symptoms presented more AECOPD (p<0.001) and more hospitalisations for AECOPD (p<0.001) in 1 year. In multivariate analysis, depressive symptoms were an independent predictor of mortality (hazard ratio 3.568, 95% CI 1.302-9.780) and risk for AECOPD (incidence rate ratio (IRR) 2.221, 95% CI 1.573-3.135) and AECOPD hospitalisations (IRR 3.589, 95% CI 2.319-5.556) in 1 year. The presence of depressive symptoms in patients admitted for AECOPD has a significant impact on recovery and is related to worse survival and increased risk for subsequent COPD exacerbations and hospitalisations in 1 year.

Entities:  

Mesh:

Year:  2012        PMID: 22878874     DOI: 10.1183/09031936.00013112

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  22 in total

1.  GWAS and systems biology analysis of depressive symptoms among smokers from the COPDGene cohort.

Authors:  Jonathan T Heinzman; Karin F Hoth; Michael H Cho; Phuwanat Sakornsakolpat; Elizabeth A Regan; Barry J Make; Gregory L Kinney; Frederick S Wamboldt; Kristen E Holm; Nicholas Bormann; Julian Robles; Victor Kim; Anand S Iyer; Edwin K Silverman; James D Crapo; Shizhong Han; James B Potash; Gen Shinozaki
Journal:  J Affect Disord       Date:  2018-09-07       Impact factor: 4.839

Review 2.  Post-COVID-19 Depressive Symptoms: Epidemiology, Pathophysiology, and Pharmacological Treatment.

Authors:  Mario Gennaro Mazza; Mariagrazia Palladini; Sara Poletti; Francesco Benedetti
Journal:  CNS Drugs       Date:  2022-06-21       Impact factor: 6.497

3.  Collateral damage: depressive symptoms in the partners of COPD patients.

Authors:  Andriana I Papaioannou; Stamatoula Tsikrika; Konstantinos Bartziokas; Foteini Karakontaki; Emmanouil Kastanakis; Filia Diamantea; Aikaterini Haniotou; Spyros Papiris; Vlassis Polychronopoulos; Stelios Loukides; Konstantinos Kostikas
Journal:  Lung       Date:  2014-05-11       Impact factor: 2.584

4.  Symptom cluster, healthcare use and mortality in patients with severe chronic obstructive pulmonary disease.

Authors:  Soo Kyung Park; Janet L Larson
Journal:  J Clin Nurs       Date:  2014-01-27       Impact factor: 3.036

Review 5.  Helping COPD patients change health behavior in order to improve their quality of life.

Authors:  Pere Almagro; Alejandra Castro
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2013-07-24

6.  Risk of pneumonia with inhaled corticosteroid/long-acting β2 agonist therapy in chronic obstructive pulmonary disease: a cluster analysis.

Authors:  Rachael L DiSantostefano; Hao Li; David Hinds; Dmitry V Galkin; David B Rubin
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2014-05-07

Review 7.  Depressive symptoms are associated with higher rates of readmission or mortality after medical hospitalization: A systematic review and meta-analysis.

Authors:  Jenelle L Pederson; Lindsey M Warkentin; Sumit R Majumdar; Finlay A McAlister
Journal:  J Hosp Med       Date:  2016-01-29       Impact factor: 2.960

8.  Screening tools for evaluation of depression in Chronic Obstructive Pulmonary Disease (COPD). A systematic review.

Authors:  K Bock; E Bendstrup; O Hilberg; A Løkke
Journal:  Eur Clin Respir J       Date:  2017-01-01

9.  Impact of a COPD comprehensive case management program on hospital length of stay and readmission rates.

Authors:  Abdulmajeed Alshabanat; Michael C Otterstatter; Don D Sin; Jeremy Road; Carmen Rempel; Jane Burns; Stephan F van Eeden; J M FitzGerald
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2017-03-21

10.  Course of COPD assessment test (CAT) and clinical COPD questionnaire (CCQ) scores during recovery from exacerbations of chronic obstructive pulmonary disease.

Authors:  Marc Miravitlles; Patricia García-Sidro; Alonso Fernández-Nistal; María Jesús Buendía; María José Espinosa de los Monteros; Jesús Molina
Journal:  Health Qual Life Outcomes       Date:  2013-08-29       Impact factor: 3.186

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.